Pacific Biosciences of California, Inc.

NASDAQ:PACB

Medical - Devices

Healthcare
$1.83 +3.17%

+$0.04 today

Market cap
$571.39M
Beta
2.32
P/E (TTM)
-3.3
EPS (TTM)
-$0.42
52W Low $1.09High $2.73

Volume 15.30M

Average 6.06M

PACB Interest Income

Income earned on cash, deposits, and investments held by the company.

Pacific Biosciences of California, Inc.NASDAQ: PACB

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income remains negative

Q1 FY2026 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $0.

Context

  • Interest income amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest income increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Income vs competitors

How PACB compares with its peers on the latest reported figures

  • PACB's LTM Mar 2026 interest income of $0 is the lowest of the 3 companies compared; the peer median is $15.87M.
  • Interest income amounts to 0.0% of revenue for PACB, versus a peer median of 47.4%.
PACB Competitors Peer median
Interest Income for PACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ILMNIllumina, Inc.LTM Jun 2026$30M -28.6%+53.8%0.7%
QSIQuantum-Si incorporatedLTM Mar 2026$1.74M ——94.2%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding PACB) $15.87M-28.6%+53.8%47.4%

Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.51M128.3M200.52M154.01M160.01M
Cost of Revenue71.65M79.27M147.74M116.73M109.33M
Gross Profit58.86M49.04M52.78M37.28M50.67M
Gross Margin45.1%38.2%26.3%24.2%31.7%
Research & Development112.9M193M187.17M134.92M97.31M
Selling, General & Admin124.12M160.85M169.82M175.02M141.49M
Operating Expenses269.3M356.23M387.25M511.6M608.24M
Depreciation & Amortization11.59M17.32M32.69M53.35M504.91M
EBITDA(250.76M)(282.24M)(271.13M)(242.77M)(34.2M)
EBITDA Margin-192.1%-220.0%-135.2%-157.6%-21.4%
Operating Income(210.44M)(307.2M)(334.47M)(474.31M)(557.56M)
Operating Margin-161.2%-239.4%-166.8%-308.0%-348.5%
Interest Income00000
Interest Expense12.53M14.69M14.34M13.41M6.95M
Other Income / Expenses(64.44M)(7.05M)16.31M164.78M11.5M
Income Before Tax(274.87M)(314.25M)(318.16M)(309.54M)(546.06M)
Pre-Tax Margin-210.6%-244.9%-158.7%-201.0%-341.3%
Income Tax Expense(93.65M)0(11.42M)316K318K
Net Income(181.22M)(314.25M)(306.74M)(309.85M)(546.38M)
Net Margin-138.9%-244.9%-153.0%-201.2%-341.5%
EPS (Basic)(0.89)(1.40)(1.21)(1.13)(1.82)
EPS (Diluted)(0.89)(1.40)(1.21)(1.07)(1.82)
Weighted Avg Shares203.62M224.55M253.63M274.49M299.96M
Weighted Avg Shares (Diluted)204.14M224.55M253.63M288.37M299.96M

Pacific Biosciences of California, Inc.

NASDAQ:PACB

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.